Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Lowering LDL cholesterol reduces the risk of atherosclerotic vascular disease in a wide range of patients with chronic kidney disease, with no evidence of a threshold below which further reductions no longer reduce risk. Statins safely lower LDL cholesterol, but novel inhibitors of proprotein convertase subtilisin kexin 9 (PCSK9) provide additional reductions which may reduce atherosclerotic vascular disease yet further in this high risk population.

Original publication

DOI

10.1016/j.kint.2018.01.030

Type

Journal article

Journal

Kidney Int

Publication Date

06/2018

Volume

93

Pages

1267 - 1269

Keywords

Antibodies, Monoclonal, Cholesterol, LDL, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertase 9, Renal Insufficiency, Chronic